BUZZ-Australia's Amplia rises to 4-month high on Eli Lilly cancer drug trial collaboration
Reuters2026/08/04 00:21** Shares of Australia's Amplia Therapeutics ATX.AX rise as much as 37% to A$0.185, hitting their highest level since April 7
** Stock posts its biggest intraday pct gain since March 23
** The pharmaceutical firm signs a clinical trial collaboration and supply agreement with Eli Lilly LLY.N
** Says the deal to test company's experimental cancer drug narmafotinib in combination with Lilly's investigational KRAS inhibitor olomorasib in a clinical trial
** ATX up over 13% this year, including the day's move
(Reporting by Rajasik Mukherjee in Bengaluru)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Tim Eriksen reports purchase of 5,500 Saker Aviation common shares worth $32,120
Credicorp posts transcript of Q2 2026 earnings call
Cocrystal Pharma appoints Carol Brosgart to board of directors
Crypto prices
More
